Greenwich Lifesciences Announces Phase 3 FLAMINGO-01 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Has Achieved A Major Milestone By Screening Over 1,000 Patients

Flamingo-01 Progress to Date

The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the equivalent of 600 patients per year in approximately 40 US sites and 100 EU sites for a total of 140 active sites. The Company is considering a strategy to continue enrolling in both the HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted and the appropriate size of each arm can be further assessed.